Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
Barry
M J
MJ
Medical Practices Evaluation Center, Massachusetts General Hospital, Boston 02114, USA.
Fleming
C
C
Coley
C M
CM
Wasson
J H
JH
Fahs
M C
MC
Oesterling
J E
JE
D000368:Aged; D003131:Combined Modality Therapy; D003452:Cryosurgery; D005500:Follow-Up Studies; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000331:legislation & jurisprudence*; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000331:legislation & jurisprudence; D006278:Medicare / Q000331:legislation & jurisprudence*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000191:economics / Q000628:therapy*; D011878:Radiotherapy; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States
D017430:Prostate-Specific Antigen